Benefits
Testosterone levels in men aged 21 to 55
In 120 healthy men aged 21 to 35, 400 mg a day for 56 days raised free and total testosterone and luteinizing hormone more than placebo, while 200 mg raised free testosterone only. In 120 men aged 36 to 55, both doses raised free and total testosterone versus placebo. Estradiol, DHT and cortisol did not change significantly.
Aging male symptom scores in men aged 36 to 55
In a 56-day trial of 120 healthy men aged 36 to 55, both 200 and 400 mg a day lowered scores on the Aging Males' Symptoms scale, which covers psychological, physical and sexual complaints, more than placebo. Grip strength and perceived stress scores also improved. The ingredient's developer funded the trial.
Sexual function and desire in men aged 40 to 70
In an 84-day trial of 120 men aged 40 to 70 with normal testosterone, mild to moderate erection problems and low sexual desire, 400 mg a day improved scores on a sexual function questionnaire, an erectile function index and an erection hardness scale more than placebo. It is one trial, funded by the developer.
Grip strength and upper arm size
In the trial of men aged 21 to 35, the 400 mg group improved grip strength and mid-upper arm circumference by the end of the study. In the trial of men aged 40 to 70, grip strength and six-minute walk distance rose more than placebo. These were secondary outcomes.
Luteinizing hormone in young men
In the trial of men aged 21 to 35, 400 mg a day raised luteinizing hormone, the pituitary signal that tells the testes to make testosterone, more than placebo. The other two trials did not report this hormone, so the finding rests on one study.
Fatigue scores in men aged 40 to 70
In the 84-day trial of 120 men aged 40 to 70, 400 mg a day lowered general, physical and mental fatigue scores from baseline. Fatigue was a secondary outcome in a single trial, and the paper gives conflicting statements on whether the total fatigue score differed from placebo at the end of the study.
Mechanism of action
Leydig cell and aromatase effects in cell studies
The developer reports that the blend increased testosterone production in mouse Leydig cells and lowered aromatase activity, the enzyme that turns testosterone into estradiol, in a human placental cell line. These cell results are only summarized in the trial papers, have not been published in full, and do not show what happens in the body.
Luteinizing hormone signaling
In the young-men trial, luteinizing hormone rose along with testosterone, which suggests the blend acts on the body's own hormone signaling rather than supplying hormone. This was measured in one trial only.
Standardized marker compounds
Punicalagins from pomegranate and theobromine from cocoa are the marker compounds used to standardize the blend. Which compounds drive the trial results has not been tested. A 400 mg dose supplies at least 2 mg of theobromine.
Clinical trials
Randomized, double-blind, placebo-controlled three-arm trial of 200 mg or 400 mg a day versus placebo for 56 days. Primary outcome: free and total testosterone (Sreeramaneni et al. 2023, Journal of Dietary Supplements).
120 healthy men aged 21 to 35, 40 per group.
Both doses raised free testosterone versus placebo; only 400 mg raised total testosterone and luteinizing hormone. DHT, cortisol and estradiol did not change significantly. The 400 mg group improved grip strength and mid-upper arm circumference. Blood, urine and vital signs stayed in normal ranges.
Randomized, double-blind, placebo-controlled three-arm trial of 200 mg or 400 mg a day versus placebo for 56 days, registered as CTRI/2019/02/017506. Primary outcome: Aging Males' Symptoms score. Funded by Laila Nutraceuticals (Pandit et al. 2022, International Journal of Medical Sciences).
120 healthy men aged 36 to 55.
Both doses lowered symptom scores, including general, psychological and sexual well-being, and raised free and total testosterone more than placebo, and grip strength and perceived stress scores improved. Estradiol, DHT and cortisol did not change significantly. Five minor adverse events were reported across all groups.
Randomized, double-blind, placebo-controlled trial of 400 mg a day versus placebo for 84 days. Primary outcome: Derogatis Interview for Sexual Functioning (male self-report). Funded by Laila Nutraceuticals (Srivastava et al. 2025, International Journal of Medical Sciences).
120 men aged 40 to 70 with total testosterone of at least 300 ng/dL, mild to moderate erection problems and low sexual desire, 60 per group.
Total and domain sexual function scores, erectile function scores and erection hardness improved more than placebo. Grip strength and six-minute walk distance also improved. Fatigue scores fell from baseline, but the paper is inconsistent on whether the total fatigue score beat placebo. Testosterone was used only for screening.